文献速递青光眼神经眼科

青光眼与神经退行性疾病风险:一项为期10年的全球真实世界数据评估

Glaucoma and Neurodegenerative Disease Risk: A 10-Year Assessment of Real-World Global Data.
PubMed 文献 · Am J Ophthalmol · 2026-08-03

该回顾性队列研究基于TriNetX数据(2005-2025),将青光眼患者按1:1倾向性匹配后,评估其新发神经退行性疾病风险。研究发现青光眼与阿尔茨海默病、血管性痴呆及帕金森病风险升高相关,且风险轨迹因发病年龄和临床亚型而异,提示人群层面的关联而非因果机制。

要点

  • 青光眼患者10年阿尔茨海默病风险升高(HR=1.485),血管性痴呆风险亦升高(HR=1.213)。
  • 早发型青光眼患者阿尔茨海默病风险延迟出现,10年时达峰值(HR=2.320)。
  • 血管性痴呆风险在原发性开角型(HR=1.203)和原发性闭角型(HR=1.224)中升高,正常眼压型无显著关联。

核心结论

  • 青光眼与后续神经退行性疾病诊断存在观察性关联,风险轨迹因发病年龄和临床亚型而异。
  • 这些发现提示人群层面的相关性,而非因果机制联系。

研究设计与样本

  • 回顾性队列研究,使用TriNetX数据(2005-2025)。
  • 青光眼患者按1:1倾向性匹配至对照,匹配因素包括基线人口学、合并症、药物和实验室指标。
  • 结局使用国际疾病分类第十版(ICD-10)代码定义。
  • 队列按年龄(<45岁 vs >65岁)和亚型(原发性开角型[POAG]、原发性闭角型[PACG]、正常眼压型[NTG])分层。
  • 共纳入384,256对匹配个体。

主要发现

  • 青光眼与10年阿尔茨海默病风险升高相关(HR=1.485;95%CI 1.427-1.546;P<.001)。
  • 青光眼与10年血管性痴呆风险升高相关(HR=1.213;95%CI 1.159-1.27;P<.001)。
  • 帕金森病风险延迟至10年达峰(HR=1.115;95%CI 1.066-1.167;P<.001)。
  • 早发型患者阿尔茨海默病风险10年达峰(HR=2.320;P=.03),晚发型患者风险早期出现。
  • 亚型分析:POAG和PACG的血管性痴呆风险升高(HR=1.203和1.224),NTG无显著关联(P=.08)。

关键数值与推荐

  • 阿尔茨海默病风险在POAG(HR=1.044;P=.10)、PACG(HR=1.096;P=.13)、NTG(HR=1.097;P=.19)中均无显著关联。
  • 血管性痴呆风险在POAG(HR=1.203;95%CI 1.129-1.281;P<.001)和PACG(HR=1.224;95%CI 1.056-1.419;P=.007)中升高,NTG无显著关联(P=.08)。
  • 轻度认知障碍风险在POAG(HR=1.201;95%CI 1.120-1.288;P<.001)和NTG(HR=1.235;95%CI 1.089-1.401;P=.001)中升高。
  • 帕金森病风险仅在NTG中显著关联(HR=1.283;95%CI 1.043-1.577;P=.018),POAG(P=.05)和PACG(P=.58)无显著相关。
  • 所有三种亚型均与未特指痴呆保持显著关联(所有P<.05)。

临床怎么用

  • 对青光眼患者,尤其早发型和特定亚型,应关注神经退行性疾病的长期监测。
  • 血管性痴呆风险在POAG和PACG中升高,提示需管理血管危险因素。
  • NTG患者需关注帕金森病和轻度认知障碍风险,POAG患者需关注轻度认知障碍风险。

局限性

  • 观察性研究设计,无法确立因果关系。
  • 结局基于ICD代码定义,可能存在编码偏倚。
  • 未报告匹配后残余混杂因素的控制情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate 10-year risk trajectories of newly diagnosed neurodegenerative diseases among glaucoma patients across age-stratified cohorts and clinical subtypes. DESIGN: Retrospective cohort study. METHODS: Using TriNetX data (2005-2025), glaucoma patients were propensity-matched 1:1 to controls based on baseline demographics, comorbidities, medications, and laboratory metrics. Outcomes were defined using International Classification of Diseases, Tenth Revision codes. Risks for mild cognitive impairment (MCI), Alzheimer's disease (AD), vascular dementia (VD), unspecified dementias, and Parkinson's disease (PD) were assessed. Cohorts were stratified by age (<45 vs >65 years) and subtype (primary open-angle [POAG], primary angle-closure [PACG], and normal-tension [NTG] glaucoma). MAIN OUTCOME MEASURES: 1-, 3-, 5-, and 10-year hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: Among 384,256 matched pairs, glaucoma correlated with elevated 10-year risks for AD (HR = 1.485; 95% CI,1.427-1.546; P < .001), VD (HR = 1.213; 95% CI, 1.159-1.27; P < .001), and a delayed PD risk peaking at 10 years (HR = 1.115; 95% CI, 1.066-1.167; P < .001). AD and VD risks emerged early in late-onset glaucoma but showed delayed emergence in early-onset patients, where AD risk peaked at 10 years (HR = 2.320; P = .03). Subtype analysis revealed no significant AD associations for POAG (HR = 1.044; P = .10), PACG (HR = 1.096; P = .13), or NTG (HR = 1.097; P = .19). However, VD risk was elevated in POAG (HR = 1.203; 95% CI, 1.129-1.281; P < .001) and PACG (HR = 1.224; 95% CI, 1.056-1.419; P = .007), but not NTG (P = .08). MCI risk increased in POAG (HR = 1.201; 95% CI, 1.120-1.288; P < .001) and NTG (HR = 1.235; 95% CI, 1.089-1.401; P = .001). NTG demonstrated the only significant PD association (HR = 1.283; 95% CI, 1.043-1.577; P = .018), while POAG (P = .05) and PACG (P = .58) showed no correlation. All 3 subtypes maintained significant associations with unspecified dementia (all P < .05). CONCLUSIONS: Glaucoma is observationally associated with subsequent neurodegenerative diagnoses, with statistical trajectories varying by onset age and clinical subtype. These findings indicate population-level correlations rather than causal mechanistic linkages.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wong MS, Wang J, Lin YH, et al. Glaucoma and Neurodegenerative Disease Risk: A 10-Year Assessment of Real-World Global Data. Am J Ophthalmol. 2026. PMID: 42546867. doi:10.1016/j.ajo.2026.07.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。